TICKERNERD
Menu
CTEVCTEVHealthcare · Health Information Services

CTEV Stock Forecast: Claritev Corp. Price Predictions for 2026-2027

Last close, 12 Oct 2026
$24
−1.34% on the day

The 5 Wall Street analysts covering Claritev Corp. hold a median 12-month price target of $43 — +76.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 12 Oct 2026 — in the upper half.

Market cap
$417.9M
Ticker Nerd rank
64 / 100
Median analyst target
$43
Analysts covering
5
Revenue$257.5M+6.6% y/y
Operating income$33.0M
Net income−$59.2M
Free cash flow$54.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.4%
1M
−32.4%
YTD
−43.1%
1Y
−54.7%
From 52W high
−65.9%
From 52W low
+80.6%
$13
$71
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CTEV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Claritev Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
97
Accruals
87
Growth
76
Size
56
Quality
48
Value
39
Issuance
38
Momentum
21
Volatility
11

Revisions (97): Analysts have, on balance, been raising their forecasts.

Volatility (11): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CTEV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTEV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70$80Jan 26Apr 26Jul 26Oct 26CTEVHigh $73Median $43Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $30Median $43High $73

The green dot is the last close — the median target sits +76.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
21 Aug 2026BarclaysMaintainsOverweight$28 → $40
12 Aug 2026Wells FargoMaintainsEqual-Weight$22 → $30
12 Aug 2026Wells FargoMaintainsEqual-Weight—
10 Aug 2026Canaccord GenuityMaintainsBuy$37 → $43
10 Aug 2026Canaccord GenuityMaintainsBuy—
10 Aug 2026CitigroupMaintainsBuy—
10 Aug 2026CitigroupMaintainsBuy$40 → $45
21 July 2026Canaccord GenuityMaintainsBuy$32 → $37
21 July 2026Canaccord GenuityMaintainsBuy—
29 May 2026Canaccord GenuityInitiatesBuy—
29 May 2026Canaccord GenuityInitiatesBuy$32
24 Apr 2026BarclaysInitiatesOverweight—
19 Mar 2026Wells FargoMaintainsEqual-Weight—
25 Feb 2026CitigroupMaintainsBuy—
24 Feb 2026GuggenheimMaintainsBuy—
24 Feb 2026Wells FargoMaintainsEqual-Weight—
9 Jan 2026CitigroupMaintainsBuy—
9 Jan 2026Wells FargoInitiatesEqual-Weight—
10 Nov 2025CitigroupMaintainsBuy—
22 Oct 2025CitigroupUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTEV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CTEV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, Claritev Corp. returned −54.7% against +20.4% for the S&P 500, dividends included.

CTEV vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26CTEVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CTEV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.8%
Analysts raising
1
Analysts cutting
0
Fundamentals

Claritev Corp. (CTEV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.4×

Cheaper than 84% of US stocks

Price / sales
0.4×

Cheaper than 84% of US stocks

Price / book
−1.5×

Cheaper than 95% of US stocks

EV / EBITDA
9.5×

Cheaper than 39% of US stocks

Growth & margins
Revenue growth (YoY)
6.6%

Higher than 43% of US stocks

Earnings growth (YoY)
6.6%

Higher than 43% of US stocks

Gross margin
67.3%

Higher than 80% of US stocks

Operating margin
12.8%

Higher than 69% of US stocks

Net margin
−28.5%

Higher than 14% of US stocks

Returns & dividend
Return on equity
170.1%

Higher than 98% of US stocks

Return on assets
1.2%

Higher than 52% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Claritev Corp. (CTEV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Claritev Corp. has a market value of $417.9M and an enterprise value of $5.1B.

  • Revenue in the twelve months to 30 June 2026: $994.7M. The latest quarter grew 6.6% year on year.

  • Net income over the same four quarters: −$283.1M, a −28.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−17.01.

  • Free cash flow in the twelve months to 30 June 2026: −$17.9M.

  • Shares outstanding: 16.9M.

  • Trailing P/E: −1.4×; forward P/E: 3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Claritev Corp. employs 3,000 people — $332K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

CTEV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
CTEVClaritev Corp.$417.9M
64
CARLCarlsmed, Inc.$401.8M
33
SLPSimulations Plus, Inc.$374.2M
—
NRCNRC Health$460.0M
90
EVHEvolent Health, Inc.$474.5M
61
WEAVWeave Communications, Inc.$590.4M
81
SOPHSOPHiA GENETICS SA$605.7M
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Claritev Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTEV news & analysis

Claritev: Revenue Growth Is Back, Cash Flow Is The Next Test

Seeking Alpha · 6 Oct 2026neutral

Seeking Alpha reports early signs of a turnaround at Claritev, with revenue and bookings growth, though growth is concentrated in Claims Intelligence. The article highlights high leverage, modest projected 2026 free cash flow, and the need for broader margin recovery and operational leverage.

Why it matters — CTEV watchers are monitoring whether revenue growth can translate into stronger cash flow and broader operating improvement amid substantial debt.

Claritev Selected by GDIT to Support CDC's World Trade Center Health Program

Business Wire · 22 Sept 2026positive

Claritev Corporation has been selected by General Dynamics Information Technology (GDIT) to support the World Trade Center Health Program, a federal healthcare program established under the James Zadroga 9/11 Health and Compensation Act. The program provides healthcare nationwide to eligible individuals.

Why it matters — This selection represents a notable new federal contract relationship for Claritev, potentially expanding its healthcare technology and data work.

Claritev Releases 2025 Corporate Responsibility Report

Business Wire · 17 Sept 2026positive

Claritev Corporation announced the publication of its 2025 Corporate Responsibility Report, which highlights the company's progress across priorities including responsible AI, employee engagement, community impact, and sustainable operations. Throughout 2025, the company focused on advancing transparency and affordability in healthcare.

Why it matters — CTEV watchers would care because the report signals the company's ongoing commitment to responsible AI, sustainability, and community-focused operations, which are key areas that can influence its reputation and long-term stakeholder relationships.

Claritev Corporation (CTEV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

Claritev Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, where its remarks were published as an event transcript by Seeking Alpha. The coverage documents the company's formal participation at the investor conference.

Why it matters — A CTEV watcher would care because the conference presentation offers direct insight into how the company communicates its business position to the investment community.

Claritev Appoints Ben Letham to its Board of Directors

Business Wire · 15 Sept 2026positive

Claritev Corporation announced the appointment of Ben Letham to its Board of Directors, effective September 14, 2026, to fill a vacancy. Letham brings extensive experience in artificial intelligence and optimization.

Why it matters — A director with deep AI expertise could help guide Claritev's long-term strategic objectives as a technology, data, and insights company.

FAQ

Frequently asked questions about CTEV stock

What is the CTEV stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Claritev Corp. have a median 12-month price target of $43, with estimates ranging from $30 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTEV stock a buy right now?

Of the 5 analysts covering Claritev Corp., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Claritev Corp. 64 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTEV?

As at 12 Oct 2026, Claritev Corp. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).

Will CTEV stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +76.7% from the last close, and Ticker Nerd's factor model ranks Claritev Corp. 64 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTEV stock forecast for 2030?

No analyst covering Claritev Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTEV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $73 over the next 12 months.

How has CTEV stock performed over the past year?

Claritev Corp. returned -54.7% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Claritev Corp. do?

Claritev Corp. Class A Common Stock is the equity security of Claritev Corporation, a healthcare technology and data services company focused on cost management, payment integrity, and revenue integrity solutions for the U.S.

What is the latest news on CTEV?

The most recent item we track (Seeking Alpha, 6 Oct 2026): "Claritev: Revenue Growth Is Back, Cash Flow Is The Next Test". Seeking Alpha reports early signs of a turnaround at Claritev, with revenue and bookings growth, though growth is concentrated in Claims Intelligence. The article highlights high leverage, modest projected 2026 free cash flow, and the need for broader margin recovery and operational leverage.

Company

About Claritev Corp.

Claritev Corp. Class A Common Stock is the equity security of Claritev Corporation, a healthcare technology and data services company focused on cost management, payment integrity, and revenue integrity solutions for the U.S. healthcare industry. The company supports health plans, providers, and other healthcare stakeholders with data analytics and technology-enabled services designed to improve claims processing, network management, and payment accuracy. Its offerings include claims intelligence, reference-based pricing, negotiation services, surprise bill services, network solutions, and pre- and post-payment integrity tools. Claritev also provides clinical negotiation and revenue integrity services that help clients manage complex healthcare transactions and administrative workflows. Headquartered in McLean, Virginia, Claritev Corp. Class A Common Stock represents ownership in a business that plays a specialized role in healthcare infrastructure by helping organizations manage cost, transparency, and claims-related processes.

CEO Mr. Travis S. Dalton · 3,000 employees · United States · https://www.claritev.com